Clinical trial

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

NCT00526045

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-07-01

PhasePHASE1 / PHASE2

Study timeline

Study start (unknown)2007-07-01Date precision: month

Registry last updated2020-12-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Hematologic Neoplasmsunresolved

Interventions

AUY922 2 mg/m2DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 St LouisMissouri, United States1 San AntonioTexas, United States1 Las VegasNevada, United States1 AugustaGeorgia, United States1 GroningenNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00526045 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.